-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-516504-42-00
5
2022-03-05
Respiratory distress syndrome in preterm infants
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-512701-11-00
4
2018-08-29
Systemic Juvenile Idiopathic Arthritis (sJIA)
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2022-502878-16-00
5
2025-01-23
Acute ischemic strokes with incomplete reperfusion
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2024-516212-24-00
4
2024-10-08
Chronic Myeloid Leukemia
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-508630-34-00
5
2024-05-28
Overweight
-
2022-500571-32-00
4
2024-05-15
Early-Stage Unfavorable Classical Hodgkin Lymphoma
-
2023-506183-13-00
4
2024-03-29
Alzheimer’s Disease
-
2024-512980-29-00
4
2023-08-28
T1-T2N0 esophageal adenocarcinoma including gastroesophageal
junction
-
2022-501576-25-00
5
2023-07-07
Melanoma